Deucravacitinib

Resumen

Alternativas con registro en Colombia

• Tofacitinib · costo anual estimado $ 24.326.155
• Baricitinib · costo anual estimado $ 25.136.090
• Upadacitinib · costo anual estimado $ 28.656.515

Estudios clínicos principales

• POETYK-PSO-2: An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to
  Fase 3 · 2018 · 1.020 participantes · Bristol-Myers Squibb · NCT03611751
• A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Bio
  Fase 3 · 2021 · 670 participantes · Bristol-Myers Squibb · NCT04908202
• POETYK-PSO-1: Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
  Fase 3 · 2018 · 666 participantes · Bristol-Myers Squibb · NCT03624127
• A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Bio
  Fase 3 · 2021 · 729 participantes · Bristol-Myers Squibb · NCT04908189

Enfermedades relacionadas

• Psoriasis y artritis psoriásica

Fuentes

• Etiqueta FDA (DailyMed): SOTYKTU
• EMA: Sotyktu